Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 24:12:965-975.
doi: 10.2147/IDR.S199844. eCollection 2019.

Molecular mechanisms related to colistin resistance in Enterobacteriaceae

Affiliations

Molecular mechanisms related to colistin resistance in Enterobacteriaceae

Zahra Aghapour et al. Infect Drug Resist. .

Abstract

Colistin is an effective antibiotic for treatment of most multidrug-resistant Gram-negative bacteria. It is used currently as a last-line drug for infections due to severe Gram-negative bacteria followed by an increase in resistance among Gram-negative bacteria. Colistin resistance is considered a serious problem, due to a lack of alternative antibiotics. Some bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacteriaceae members, such as Escherichia coli, Salmonella spp., and Klebsiella spp. have an acquired resistance against colistin. However, other bacteria, including Serratia spp., Proteus spp. and Burkholderia spp. are naturally resistant to this antibiotic. In addition, clinicians should be alert to the possibility of colistin resistance among multidrug-resistant bacteria and development through mutation or adaptation mechanisms. Rapidly emerging bacterial resistance has made it harder for us to rely completely on the discovery of new antibiotics; therefore, we need to have logical approaches to use old antibiotics, such as colistin. This review presents current knowledge about the different mechanisms of colistin resistance.

Keywords: Enterobacteriaceae; colistin; lipid A; mcr genes; two-component system.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Regulation and plasmid-mediated pathways of lipopolysaccharide modifications in Enterobacteriaceae.

Similar articles

Cited by

References

    1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48(1):1–12. doi:10.1086/595011 - DOI - PubMed
    1. Health UDo, Control HSJCfD. Prevention. Antibiotic resistance threats in the United States. 2013;2013.
    1. Shlaes DM, Sahm D, Opiela C, Spellberg B. chemotherapy. Commentary: the FDA reboot of antibiotic development. Antimicrob Agents Chemother. 2013;57(10):4605-4607. - PMC - PubMed
    1. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis. 2006;42(5):657–668. doi:10.1086/499819 - DOI - PubMed
    1. Tenover FC, McGowan JE Jr. Reasons for the emergence of antibiotic resistance. Am J Med Sci. 1996;311(1):9–16. - PubMed